论文部分内容阅读
为了解肺炎并发心衰患儿与血浆内皮素（ET）之间的关系，以及应用扩血管、强心药物治疗后对其的影响，我们对65例肺炎患儿进行了治疗前后血浆ET测定。结果表明：治疗前肺炎患儿血浆ET均增高，以重症肺炎及并发心衰者增高尤为显著（P＜0．01）；轻型肺炎组与对照组血浆ET增高无显著性差异（P＞0．05）。治疗后各组ET值均下降（P分别＜0．05、＜0．001），重症肺炎组ET浓度虽下降显著（P＜0．001），但仍维持高水平，且与其他各组比较有显著性差异（P均＜0．01）。提示单纯应用扩血管药物不能完全降低血浆ET水平，而扩血管药物与西地兰合用，可有效地对抗血浆ET。因此，我们认为西地兰在保护小儿心肺功能方面，对血浆ET有较好的拮抗作用。
To understand the relationship between pneumonia and children with heart failure and plasma endothelin (ET), and the application of vasodilators, cardiac effects after drug treatment, we have 65 cases of children with pneumonia before and after treatment of plasma ET assay. The results showed that the plasma ET levels of children with pneumonia before treatment increased significantly, especially those with severe pneumonia and complicated with heart failure (P <0.01). There was no significant difference in plasma ET between mild pneumonia group and control group (P> 0.05). 05). After treatment, the ET values of all the groups decreased (P <0.05, <0.001), while the levels of ET in severe pneumonia group decreased significantly (P <0.001), but remained high, and compared with other groups There was significant difference (all P <0.01). Prompt application of vasodilators alone can not completely reduce the level of plasma ET, and vasodilator drugs combined with cedilanid, can effectively combat the plasma ET. Therefore, we believe that cedilanid in the protection of children’s cardiopulmonary function, the plasma ET has a better antagonistic effect.